コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 3H(2)O] at a rate that increased linearly with pCO(2).
2 3H-Diazirines were thermolyzed or photolyzed to generate
3 [3H]-Riboflavin uptake is saturable with K(m) and V(max)
4 [3H]PiB autoradiography and immunocytochemistry for beta-
6 -[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols which are potent and
7 approach to 5- or 4-substituted benzoxepin-1(3H)-ones by combining the hydroarylative/hydrovinylative
8 lbenzoic acids 1 or 3-hydroxyisobenzofuran-1(3H)-ones 2 with hydrazine to generate phthalazin-1(2H)-o
9 ',4',5',6'-tetrahydroxyspiro[isobenzofuran-1(3H),9'-(9H)xanthen]-3-one), and M119 (cyclohexanecarboxy
10 While the formation of an isobenzofuran-1(3H)-imine with two bulky substituents under Larock condi
13 3-[(alkoxycarbonyl)methylene]isobenzofuran-1(3H)imines were selectively obtained when the oxidative c
14 one-flask procedure to give benzo[c]oxepin-1(3H)-ones directly from the starting alkyne has been also
15 e S to N alkyl migration of substituted S-(1(3H)-isobenzofuranon-3-yl)isothiuronium bromide to N,N'-d
16 ap-101), 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl}pyrrolidine-2-ca rboxamide
17 thro-pentofuranosyl)pyrimido-[1,2-a]purin-10(3H)-one (M(1)dG) is the major adduct derived from the re
19 tetrahydro-8-hydroxypyrimido[1, 2a] purin-10(3H)-ones, commonly referred to as the gamma-OH-PdG adduc
20 spiro[3H-indole-3,2'(1H)quinazoline]-2,4'(1H,3H)dione 8, which was also identified as an intermediate
21 y intermediate 5-amino-6-ribitylamino-2,4(1H,3H) pyrimidinedione 5'-phosphate (ARPP) has not been cha
22 5-Nitro-6-(2-hydroxystyryl)pyrimidine-2,4(1H,3H)-dione (9) was identified as a novel inhibitor of Sch
23 ethyl-1-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione displayed equal potency in the new assays, in
24 -(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione) were synthesized by reaction of 6-[(3,5-dimet
25 from 7-aminopyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, a Janus-type nucleobase, has been synthesized
26 alogue, containing 5-aminoquinazoline-2,4(1H,3H)-dione, acts as a Forster resonance energy transfer a
27 Specifically, a 5-methoxyquinazoline-2,4(1H,3H)-dione-based emissive uracil analogue was identified
28 th types, uses 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione and tyrosine as substrates but not 4
29 reaction of 5-amino-6-D-ribitylamino-2,4(1H,3H)-pyrimidinedione(1) with (S)-3,4-dihydroxybutanone 4-
30 phenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione (8), a potent and highly selective Ca(V)1.
31 e following main TPs: 1-(2-benzoic acid)-(1H,3H)-quinazoline-2,4-dione (BaQD), 1-(2-benzoic acid)-(1H
32 ine-2,4-dione (BaQD), 1-(2-benzoic acid)-(1H,3H)-quinazoline-2-one (BaQM), 9-aldehyde-acridine, 9-car
33 ith Pb(OAc)4 or hydrogen abstraction from 1H-3H by the tert-butoxyl radical and characterized by UV-v
35 ecies have been generated by oxidation of 1H-3H with Pb(OAc)4 or hydrogen abstraction from 1H-3H by t
39 s of 3-(pyrimidin-2(1H)-ylidene)benzofuran-2(3H)-ones and 6-methyl-3-(pyridin-2(1H)-ylidene)benzofura
40 lorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one [CGP-37157 (CGP)], a benzothiazepine derivative
41 lidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one), provided with an high lipophilicity index and
42 Glycine-derived 1H-benzo[e][1,4]diazepin-2(3H)-ones (BZDs) 5d-g featuring C9- and N1- substitution
43 mino-acid derived 1H-benzo[e][1,4]diazepin-2(3H)-ones (BZDs) undergo highly retentive deprotonation/a
44 oxaldehyde, 1-hydroxy-2-propanone, dihydro-2(3H)-furanone, 5-methyl-(E)-2-hepten-4-one, acetic acid,
45 -N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetra methyl-cyclopropanecarboxamid
46 )-N-(3-(4-fluorobutyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl-c yclopropanecarboxamid
48 1,4'-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1 (TBPB) displays unprecedented functional selectivi
49 lohexylpiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1 (VCP794), lost agonistic selectivity for the M(1)
50 )piperidin-1-yl)butyl)-1H-benzo[d]imidazol-2(3H)-one (79) and 1-(6-(4-(4-fluorobenzoyl)piperidin-1-yl
51 )piperidin-1-yl)hexyl)-1H-benzo[d]imidazol-2(3H)-one (81) were identified as full antagonist ligands
52 nalogues 1'-beta-[1-naphtho[2,3-d]imidazol-2(3H)-one)]-2'-deoxy-d-ribofuranose and 1'-beta-[1-naphtho
53 amine-bearing N-alkylated benzo[d]imidazol-2(3H)-ones, imidazo[4,5-b]pyridin-2(3H)-ones, imidazo[4,5-
55 , 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio)benzoic acid (GRI977143), 4,5-dichlor
56 um thermolysis (FVT) of 3-methylidenefuran-2(3H)-ones 3 causes cheletropic extrusion of CO with forma
57 1b), and 3-methyl-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3b) affords the nitrile imine (2b), which rearr
58 tylphenyl)ethyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one (JZP-327A, 51), inhibited human recombinant FAAH
59 f) led to the formation of 1,3,4-oxadiazol-2(3H)-ones (4a-f, 5a) and dibenzo[c,e]azepines (6a-f) when
61 o[4,5-c]pyridin-2(3H)-ones, benzo[d]oxazol-2(3H)-ones, oxazolo[4,5-b]pyridin-2(3H)-ones and N,N'-dial
62 methyl)-tetrahydrofuran-2-yl)-1H-perimidin-2(3H )-one] (dPer) recognizes in DNA the O(6)-benzyl-2'-de
65 d]oxazol-2(3H)-ones, oxazolo[4,5-b]pyridin-2(3H)-ones and N,N'-dialkylated benzo[d]imidazol-2(3H)-one
66 to 3-benzylidene-1H-pyrrolo[2,3-b]pyridin-2(3H)-ones, as these substrates are exocyclic methylene la
67 ]pyridin-2(3H)-ones, imidazo[4,5-c]pyridin-2(3H)-ones, benzo[d]oxazol-2(3H)-ones, oxazolo[4,5-b]pyrid
68 imidazol-2(3H)-ones, imidazo[4,5-b]pyridin-2(3H)-ones, imidazo[4,5-c]pyridin-2(3H)-ones, benzo[d]oxaz
71 z)(4)}(CN)(3)](2)[Co(bik)(2)](2)}(ClO(4))(2).3H(2)O [B(pz)(4) = tetrapyrazolylborate, bik = bis(1-met
74 yl-8,9-disubstituted-6,9-dihydro-1H-purin-2-(3H)-ones 25-26 were synthesized in one step using formic
76 asibility of bypassing the high energy 2e(-)/3H(+)-intermediate through disproportionation of earlier
78 esented by cyclothiazide and the ampakine 2H,3H,6aH-pyrrolidino(2,1-3',2')1,3-oxazino(6',5'-5,4)benzo
81 here PR(3) = P(OPh)(3) ([2H]BF(4)); PPh(3) ([3H]BF(4)); PPh(2)Py ([4H]BF(4), where Py = 2-pyridyl).
84 ed are those reported in Figures 3C, 3D, 3G, 3H, 5A and 5B, and in Supplemental Figures 3A and B.
86 give N-unsubstituted 1H-2,3-benzoxazine-1,4(3H)-diones (17a-e) at rates that were dependent on tempe
87 des and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as potential antiosteoclastogenic
88 des and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-diones could be potential lead compounds for the dev
91 d efficient synthesis of 2-aminoquinazolin-4(3H)-ones and N1-substituted 2-aminoquinazolin-4(1H)-ones
92 r, these results suggest 2-aminoquinazolin-4(3H)-ones as perspective leads for future development of
93 he structure showed that 2-aminoquinazolin-4(3H)-ones bind to the open flap conformation of the enzym
95 pharmaceutically relevant 3-arylquinazolin-4(3H)-ones (quinazolinones) with high levels of enantioind
96 inazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(3H)-one RNAsplicing inhibitor), was studied in more deta
97 3(2H)-ones and 2-phenyl-5-hydroxypyrimidin-4(3H)-ones were synthesized and evaluated as endonuclease
98 esence of HCl to produce 2-chloro-3-phenyl-4(3H)-quinazoliniminium chloride (Qz) involves the formati
99 ersion reactions were studied of pyrimidin-4(3H)-imine (PMI), pyridin-2(1H)-imine (PYI), and 1H-purin
101 yl-2-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4(3H)-one (DNTP) occupies the interface between the p66 ri
102 gue (5-hydroxy-2-(4-fluorophenyl)pyrimidin-4(3H)-one) did exhibit significant activity as an endonucl
103 amino-6-ethyl-5-iodothieno[2,3-d]pyrimidin-4(3H)-one, 7, to which various arylthiols were attached at
105 oro-6-fluorobenzyl)-2-(alkylthio)pyrimidin-4(3H)-ones (2-Cl-6-F-S-DABOs) 7-12 and the related 6-(2,6-
106 ated tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-ones with mesyl, tosyl, and p-cyanobenzenesulfonyl c
107 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysin
108 carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one (compound 2) as an antibiotic effective in vivo
109 yl)pyridin-3-yl)meth yl)benzo[h]quinazolin-4(3H)-one (referred to herein as benzoquinazolinone 12) as
110 no-9H-purin-9-yl pendant to the quinazolin-4(3H)-one nucleus of both aS and aR isomers of 1 had a cri
111 around the bond connecting the quinazolin-4(3H)-one nucleus to the o-tolyl is sterically hampered, w
112 -yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one)] is a potent PI3K inhibitor selective for the d
114 brary of 26 synthetic, sulfated quinazolin-4(3H)-ones (QAOs) resulting in the identification of six m
115 easy access to 2-(alpha-styryl)quinazolin-4(3H)-ones and 3-(alpha-styryl)-1,2,4-benzothiadiazine-1,1
118 he one-pot cascade synthesis of quinazolin-4(3H)-ones via acceptorless dehydrogenative coupling of o-
119 A wide variety of substituted quinazolin-4(3H)-ones were synthesized in high yields starting from r
120 roviding an expedient access to quinazolin-4(3H)-ones, N-aryl-2-arylbenzimidazoles, and 4H-3,1-benzox
125 action of methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone, Quaalude), an infamous sedative-hypno
126 of 6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-4(3H)-ol (4-OH), which rapidly isomerizes to a 3,4-dihydro
127 tion and yielded 3-arylbenzo-1,2,3-triazin-4(3H)-ones in good to moderate yields in the presence of o
128 ive formation of 3-arylbenzo-1,2,3-triazin-4(3H)-ones in the presence of CO and1-aryl-(1H)-benzo-1,2,
129 he corresponding 3-arylbenzo-1,2,3-triazin-4(3H)-ones with high selectivity and in excellent yields.
131 ,-trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-d ione (17f), which acts as a dual human A(2a) an
132 ,7-trimethyl-3a,4-dihydro-2,1-benzisoxazol-5(3H)-ylidene)ethanal (10), the trans isomers recombined f
133 access to new oxazolo[3,2-d][1,4]oxazepin-5(3H)-ones starting from alpha-bromoamido alcohols and Mic
134 nits in the linear nucleocapsid, and a (5H + 3H) motif that forms a proper cavity for sequestration o
136 (3-methyl-2-bute n-1-yl)-2H-1-benzopyran-4,7(3H,8H)-dione; 3-[(2-O-beta-d-glucopyranosyl-beta-d-gluco
137 raightforward synthesis of various 2-alkynyl-3H-imidazo[4,5-b]pyridines, a valuable scaffold in drug
138 tuted 2,3-dihydro-1H-2-benzazepin-1-ones and 3H-2-benzoxepin-1-ones by an I-MCR/Wittig sequence was d
139 rd well-characterized hydrides ([2H](+) and [3H](+)) and mixed-valence derivatives ([2](+) and [3](+)
142 (CQ)-dependent yeast growth inhibition and [3H]CQ transport specifically due to a given PfCRT isofor
144 gulation of SREBP1c, ACC, FAS, and SCD1 and [3H]H2O incorporation into lipids), FB treatment markedly
146 raphic properties of [3H]GlcNAc-P-P-Und and [3H]GalNAc-P-P-Und, suggesting that strain O157 contained
147 olites, the detected transport from applied [3H]IBA may have resulted from the transport of IBA metab
149 has been suggested that stoichiometry may be 3H(+)/2e(-) based on the identification of only 3 proton
150 Because the isotopic discrimination between 3H and H is small, organically bound tritium (OBT) and H
151 esityl (3H(Phl(Mes))), 2,6-bismethoxyphenyl (3H(Phl(OMe))), 4-nitrophenyl (3H(Phl(NO2))), or 4-tert-b
152 metabolically labeled with [3H]GlcNAc, both [3H]GlcNAc-P-P-Und and [3H]GalNAc-P-P-Und were detected.
154 s treated with 2 equiv of KC8 and LiB(sec-Bu)3H to yield a deep blue-colored dicarbene zinc compound
156 the rate constant for transfer from CpCr(CO)3H to n-butyl vinyl ether and have examined the chemistr
157 e only inhibitor that did not also decrease [3H]2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane (WIN
158 )TiCl(thf)2 ] (2) can access the dianionic [(3H-pyr-ONO)TiCl2 (thf)] (1-THF) and monoanionic [(3H,4H-
159 t both the in situ synthesis of 3,3-difluoro-3H-indol-2-yl (OFox) glycosyl donors and activation ther
160 mediated glycosylations wherein 3,3-difluoro-3H-indol-2-yl (OFox) imidates were found to be key inter
161 pyrrol-6-ones (10), and 1-phenyl-1,2-dihydro-3H-benzo[4,5]thieno[2,3-c]pyrrol-3-ones (12)), and notab
162 dazol-3-yl benzoates and 2-alkyl-1,2-dihydro-3H-indazol-3-ones, which are known privileged structures
165 und 2) and N-{4-[4-2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]benzoyl} *-L-glut
166 e carbons (N-{4-[3-2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)propyl]benzoy l}-L-glut
168 38), a digoxigenin derivative that displaces 3H-ouabain from Na+, K+ -ATPase, and attenuates some for
170 anthranilate then affords 2,3-disubstituted-3H-quinazolin-4-ones in good to excellent yields under m
172 , N-[1(R)-1, 2-dihydro-1-ethanesulfonylspiro-3H-indole-3,4'-piperidin)-1'-yl]carbonyl-2-(pheny lmetho
175 phorylations on eukaryotic initiation factor 3H (eIF3H), a protein integral to overall eukaryotic pro
176 ylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro- 3H-quinazolin-4-one), a noncompetitive antagonist of AMP
177 de binding to generate complexes of the form 3H(Phl(R)).2F(-) modulates the redox potentials of the p
178 s and intestinal permeability to the gliadin 3H-p31-49 peptide were analyzed in polarized monolayers
180 9aR)-2-amino-6,7-dihydroxy-8-(hydroxymethyl)-3H,4H,5H,5aH,6H,7H,8H, 9aH,10H-pyrano[3,2-g]pteridin-4-o
182 The re-expression of AQP3, which increased [3H]glycerol uptake, also induced mRNA and protein expres
183 kade of which was found to partially inhibit 3H-thymidine incorporation as a result of increased cell
184 or SIgA against p31-49, transport of intact 3H-p31-49 increased significantly across Caco-2 monolaye
188 such as melittin (2845 Da), CID of the [M + 3H](3+), [M + 4H](4+), and [M + 5H](5+) ions yields amin
190 cting CCS values remained similar for the [M+3H](3+) ions observed as the glycan antennae were shorte
191 MDR1-WT (expresses wild-type P-gp), LLC-MDR1-3H (expresses common haplotype P-gp), and LLC-MDR1-3HA (
192 , cytotoxicity assays show that the LLC-MDR1-3H cells are more resistant to mitoxantrone than the LLC
193 ary pentafluorophenyl (3H(Phl(F))), mesityl (3H(Phl(Mes))), 2,6-bismethoxyphenyl (3H(Phl(OMe))), 4-ni
194 of 1, adamantane-1-carboxylic acid (3-methyl-3H-benzothiazol-2-ylidine) hydrazide, a potent KCNQ2/Q3
196 [[2-(1H-tetrazol-5-yl)biphe nyl-4-yl]methyl]-3H-imidazo[4,5-b]pyridine ((11)C-KR31173) was injected i
197 r-ONO)TiCl2 (thf)] (1-THF) and monoanionic [(3H,4H-pyr-ONO)TiCl2 (OEt2 )][B{3,5-(CF3 )2 C6 H3 }4 ] (3
198 of this binding is supported by neocortical [3H]PiB binding in regions of amyloid deposition in the p
200 methoxyphenyl (3H(Phl(OMe))), 4-nitrophenyl (3H(Phl(NO2))), or 4-tert-butylcarboxyphenyl (3H(Phl(CO2t
205 was evaluated by radioligand displacement of 3H-PK 11195 with PBR06 in vitro and by displacement of 1
209 unprecedented enantioselective synthesis of 3H pyrroles, a simple procedure using PPh3 produced a wi
212 , which can be prepared by deprotonation of [3H]BF(4) with NaOMe, is about 10(4) stronger base than i
213 nity (IC50 of 8.9 nmol) for displacement of [3H]ifenprodil, thus showing improved potency with respec
215 The regional and laminar distributions of [3H]CUMI-101 binding in baboon and human brain sections m
217 titatively track RCT following injection of [3H]-cholesterol-loaded macrophages upstream of blocked o
218 chemical and chromatographic properties of [3H]GlcNAc-P-P-Und and [3H]GalNAc-P-P-Und, suggesting tha
221 ]GalNAc, neither the enzymatic synthesis of [3H]GlcNAc-P-P-Und nor [3H]GalNAc-P-P-Und was detected.
224 B{C6 H3 (CF3 )2 }4 ] yields [(3H,4H-pyr-ONO)(3H-pyr-ONO)Zr][B{3,5-(CF3 )2 C6 H3 }4 ] (5), thus demons
225 the 2,3-dihydro-1H-2-benzazepin-1-ones 8 or 3H-2-benzoxepin-1-ones 10 in good yields via a sequentia
226 aque-associated amyloid immunoreactivity or [3H]PiB binding was seen in cerebellar gray matter in aut
227 or human brain sections, thereby ruling out [3H]CUMI-101 binding to alpha1-adrenergic receptors.
228 necarboxylic acid [2-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-(9CI)]) suppressed citral's inhibition
229 removable protecting group, (6-hydroxy-3-oxo-3H-xanthen-9-yl)methyl (1), with a molar absorption coef
230 )-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta [g]quinazolin-6-yl]amino]benzoyl]-l-gamma-
231 t cytotoxic agent 4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-N-(3-pyrid y
234 hostatin A or SAHA, H1299 cells carrying p21-3H showed a significant increase of luciferase activity,
236 riven triple-fused reporter gene system (p21-3H) to evaluate the efficacy of HDACI and the ganciclovi
238 Furthermore, when cells transfected with p21-3H or p21/PstI-3H (which lacks p53-binding sites) were t
240 vatives contain ancillary pentafluorophenyl (3H(Phl(F))), mesityl (3H(Phl(Mes))), 2,6-bismethoxypheny
241 6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl )piperazin-1-yl)methyl)-5-
243 azoles 14 in diphenyl ether affords 2-phenyl-3H-imidazo[4,5-b]quinoline-9-carbonitriles 15 in near qu
246 phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and po
247 constant for the complex between protonated [3H]vesamicol and VAChT decreases from 12 nM at neutral p
248 en cells transfected with p21-3H or p21/PstI-3H (which lacks p53-binding sites) were treated, the inc
250 (H2O)n (n = 0 to approximately 50) and [SP + 3H](3+) (H2O)n (n = 0 to approximately 30), and that maj
252 and contains a single Substance P (SP) [SP + 3H](3+) ion (SP(3+); amino acid sequence RPKPQQFFGLM-NH2
254 ble spiro-oxindole compounds bearing a spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one scaffold that are n
256 amide led to the spirocyclic molecule, spiro[3H-indole-3,2'(1H)quinazoline]-2,4'(1H,3H)dione 8, which
259 preparation of 2-hydroxy-5,6,7,7a-tetrahydro-3H-pyrrolizin-3-ones and 2-hydroxy-6,7,8,8a-tetrahydroin
260 ch as 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c] quin oline-8-sulfonamide (4BP-TQS) acti
261 ,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8- sulfonamide) have the combi
262 nist, cis-cis-4-p-tolyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4MP-TQS), toget
263 QS (4-(naphthalen-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide ) and allosteric
264 QS (4-(4-chloroophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide )] or an iodine
265 TQS (4-(4-fluorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide) ] generated a c
266 -TQS (4-(2-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide) and 3BP-TQS (4-
267 -TQS (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide) interact at an
268 -TQS (4-(3-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide), rather than at
269 -TQS (4-(4-iodoophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide)] results in com
270 cemic 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide, is a strong pos
275 umulates to lower intracellular levels than [3H]ER-076349, yet is retained longer and at higher level
276 ake and washout/retention studies show that [3H]eribulin accumulates to lower intracellular levels th
277 DNA methylation was measured using the [3H]-methyl incorporation assay, which provides disintegr
278 ,7r)-3,5-dimethyladamantan-1-yl)-4-(3-thioxo-3H-1,2-dithiol-4-yl)-ben zamide (S-memantine) and examin
279 ing a slow releasing H(2)S donor 4-(3-thioxo-3H-1,2-dithiol-4-yl)-benzoic acid (ACS48) with a NMDAR a
280 liferation was evaluated using 3H-thymidine (3H-TdR) uptake, carboxyfluorescein diacetate, succinimid
281 toichiometry has changed from 4H(+)/2e(-) to 3H(+) or 2H(+)/2e(-) without affecting the direct coupli
282 lyzes the transformation of 2-nitroarenes to 3H-indoles through a tandem cyclization-[1,2] shift reac
284 amino)ethoxy)ethoxyl]-4-[2-(trifluoromethyl)-3H-dia zirin-3-yl]benzoyl]-1,3-bis(mannopyranosyl-4-ylox
285 omers of ethyl 1-(1-(4-(3-((trifluoromethyl)-3H-diazirin-3-yl)phenyl)ethyl)-1H-imidazole-5-carbo xyla
286 -2-yn-1-yloxy)methyl)-5-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenol, AziPm-click (1)), for affinity-
287 (3)H]TDBzl-etomidate (4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzyl-[(3)H]1-(1-phenylethyl)-1H-imida
288 propofol (2-isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol ([(3)H]AziPm)) to identify propo
290 etomidate (ethyl-1-(1-(4-(3-trifluoromethyl)-3H-diazirin-3-yl)phenylethyl)-1H-imidazole-5-c arboxylat
291 -2-O-[9-[[[2-[(125)I]iodo-4-(trifluoromethyl-3H-diazirin-3-yl)ben zyl]oxy]carbonyl]nonanoyl]-sn-glyce
292 -2-O-[9-[[[2-[(125)I]iodo-4-(trifluoromethyl-3H-diazirin-3-yl)ben zyl]oxy]carbonyl]nonanoyl]-sn-glyce
293 molar potencies, including 6-trifluoromethyl-3H-benzoimidazole-4-carboxylic acid [3-(1H-tetrazol-5-yl
294 rexpressing strain, were incubated with UDP-[3H]GalNAc, neither the enzymatic synthesis of [3H]GlcNAc
295 ns from strain O157 were incubated with UDP-[3H]GlcNAc, two enzymatically labeled products were obser
297 lymphocyte proliferation was evaluated using 3H-thymidine (3H-TdR) uptake, carboxyfluorescein diaceta
298 strain O157 was metabolically labeled with [3H]GlcNAc, both [3H]GlcNAc-P-P-Und and [3H]GalNAc-P-P-Un
299 y [H(OEt2 )2 ][B{C6 H3 (CF3 )2 }4 ] yields [(3H,4H-pyr-ONO)(3H-pyr-ONO)Zr][B{3,5-(CF3 )2 C6 H3 }4 ] (
300 razin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H -imidazo[4,5-b]pyridine (27e), a potent inhibitor of
301 ro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin -4-one (28), identified following a careful
302 ro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (7) and the optimization of this new
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。